142 related articles for article (PubMed ID: 29540198)
1. Evaluation of tumor M2-pyruvate kinase (Tumor M2-PK) as a biomarker for pancreatic cancer.
Bandara IA; Baltatzis M; Sanyal S; Siriwardena AK
World J Surg Oncol; 2018 Mar; 16(1):56. PubMed ID: 29540198
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic and prognostic value of plasma tumor M2 pyruvate kinase in periampullary cancer: evidence for a novel biological marker of adverse prognosis.
Goonetilleke KS; Mason JM; Siriwardana P; King NK; France MW; Siriwardena AK
Pancreas; 2007 Apr; 34(3):318-24. PubMed ID: 17414054
[TBL] [Abstract][Full Text] [Related]
3. Factors predicting survival and pathological subtype in patients with ampullary adenocarcinoma.
Okano K; Oshima M; Yachida S; Kushida Y; Kato K; Kamada H; Wato M; Nishihira T; Fukuda Y; Maeba T; Inoue H; Masaki T; Suzuki Y
J Surg Oncol; 2014 Aug; 110(2):156-62. PubMed ID: 24619853
[TBL] [Abstract][Full Text] [Related]
4. Tumor M2-pyruvate kinase, a new metabolic marker for pancreatic cancer.
Ventrucci M; Cipolla A; Racchini C; Casadei R; Simoni P; Gullo L
Dig Dis Sci; 2004 Aug; 49(7-8):1149-55. PubMed ID: 15387337
[TBL] [Abstract][Full Text] [Related]
5. Comparison of plasma Tu-M2-PK and CA19-9 in pancreatic cancer.
Joergensen MT; Heegaard NH; Schaffalitzky de Muckadell OB
Pancreas; 2010 Mar; 39(2):243-7. PubMed ID: 19820423
[TBL] [Abstract][Full Text] [Related]
6. [Usefulness of plasma tumor M2-pyruvate kinase in the diagnosis of gastrointestinal cancer].
Kim CW; Kim JI; Park SH; Han JY; Kim JK; Chung KW; Sun HS
Korean J Gastroenterol; 2003 Nov; 42(5):387-93. PubMed ID: 14646575
[TBL] [Abstract][Full Text] [Related]
7. Current status of tumor M2 pyruvate kinase (tumor M2-PK) as a biomarker of gastrointestinal malignancy.
Hathurusinghe HR; Goonetilleke KS; Siriwardena AK
Ann Surg Oncol; 2007 Oct; 14(10):2714-20. PubMed ID: 17602267
[TBL] [Abstract][Full Text] [Related]
8. Tumor type M2 pyruvate kinase (TuM2-PK) as a novel plasma tumor marker in melanoma.
Ugurel S; Bell N; Sucker A; Zimpfer A; Rittgen W; Schadendorf D
Int J Cancer; 2005 Dec; 117(5):825-30. PubMed ID: 15957165
[TBL] [Abstract][Full Text] [Related]
9. Cytokeratin-positive cells in the bone marrow from patients with pancreatic, periampullary malignancy and benign pancreatic disease show no prognostic information.
Hugenschmidt H; Labori KJ; Brunborg C; Verbeke CS; Seeberg LT; Bendigtsen Schirmer C; Renolen A; Borgen E; Naume B; Wiedswang G
BMC Cancer; 2020 Nov; 20(1):1107. PubMed ID: 33198661
[TBL] [Abstract][Full Text] [Related]
10. Prediction of carcinoma after resection in subjects with ampullary adenomas on endoscopic biopsy.
Kim HN; Kim KM; Shin JU; Lee JK; Lee KT; Lee KH; Kim KM; Lim JH
J Clin Gastroenterol; 2013 Apr; 47(4):346-51. PubMed ID: 23442830
[TBL] [Abstract][Full Text] [Related]
11. Substaging Nodal Status in Ampullary Carcinomas has Significant Prognostic Value: Proposed Revised Staging Based on an Analysis of 313 Well-Characterized Cases.
Balci S; Basturk O; Saka B; Bagci P; Postlewait LM; Tajiri T; Jang KT; Ohike N; Kim GE; Krasinskas A; Choi H; Sarmiento JM; Kooby DA; El-Rayes BF; Knight JH; Goodman M; Akkas G; Reid MD; Maithel SK; Adsay V
Ann Surg Oncol; 2015 Dec; 22(13):4392-401. PubMed ID: 25783680
[TBL] [Abstract][Full Text] [Related]
12. [Analysis of prognosis-associated factors in pancreatic head and peri-ampullary cancer].
Roder JD; Siewert JR
Chirurg; 1992 May; 63(5):410-5. PubMed ID: 1376655
[TBL] [Abstract][Full Text] [Related]
13. Survival and prognostic factors in pancreatic and ampullary cancer.
Lemke J; Schäfer D; Sander S; Henne-Bruns D; Kornmann M
Anticancer Res; 2014 Jun; 34(6):3011-20. PubMed ID: 24922667
[TBL] [Abstract][Full Text] [Related]
14. Distribution and pathological features of pancreatic, ampullary, biliary and duodenal cancers resected with pancreaticoduodenectomy.
Chandrasegaram MD; Chiam SC; Chen JW; Khalid A; Mittinty ML; Neo EL; Tan CP; Dolan PM; Brooke-Smith ME; Kanhere H; Worthley CS
World J Surg Oncol; 2015 Feb; 13():85. PubMed ID: 25890023
[TBL] [Abstract][Full Text] [Related]
15. Circulating Tumor Cells are an Independent Predictor of Shorter Survival in Patients Undergoing Resection for Pancreatic and Periampullary Adenocarcinoma.
Hugenschmidt H; Labori KJ; Brunborg C; Verbeke CS; Seeberg LT; Schirmer CB; Renolen A; Borgen EF; Naume B; Wiedswang G
Ann Surg; 2020 Mar; 271(3):549-558. PubMed ID: 30216219
[TBL] [Abstract][Full Text] [Related]
16. [Results of surgical treatment in ampullary and pancreatic carcinoma and its prognostic parameters after R0-resection].
Ridwelski K; Meyer F; Schmidt U; Lippert H
Zentralbl Chir; 2005 Aug; 130(4):353-61. PubMed ID: 16103961
[TBL] [Abstract][Full Text] [Related]
17. Elevated CA 19-9 is associated with worse survival in patients with resected ampullary adenocarcinoma.
Boyev A; Prakash LR; Chiang YJ; Newhook TE; Bruno ML; Arvide EM; Dewhurst WL; Kim MP; Ikoma N; Lee JE; Snyder RA; Tzeng CD; Katz MHG; Maxwell JE
Surg Oncol; 2023 Dec; 51():101994. PubMed ID: 37742542
[TBL] [Abstract][Full Text] [Related]
18. Prognostic indicators following curative pancreatoduodenectomy for pancreatic carcinoma: A retrospective multivariate analysis of a single centre experience.
Petrou A; Soonawalla Z; Silva MA; Manzelli A; Moris D; Tabet PP; Friend P
J BUON; 2016; 21(4):874-882. PubMed ID: 27685908
[TBL] [Abstract][Full Text] [Related]
19. Preoperative platelet count predicts survival after resection of periampullary adenocarcinoma.
Schwarz RE; Keny H
Hepatogastroenterology; 2001; 48(41):1493-8. PubMed ID: 11677994
[TBL] [Abstract][Full Text] [Related]
20. TUM2-PK (pyruvate kinase type tumor M2), CA19-9 and CEA in patients with benign, malignant and metastasizing pancreatic lesions.
Cerwenka H; Aigner R; Bacher H; Werkgartner G; el-Shabrawi A; Quehenberger F; Mischinger HJ
Anticancer Res; 1999; 19(1B):849-51. PubMed ID: 10216504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
